Lower expression of NOTCH components in peripheral blood mononuclear cells of allogeneic hematopoietic cell transplant patients
- PMID: 35840487
- PMCID: PMC10499572
- DOI: 10.1016/j.htct.2022.05.005
Lower expression of NOTCH components in peripheral blood mononuclear cells of allogeneic hematopoietic cell transplant patients
Abstract
Introduction: Chronic graft-versus-host disease (cGvHD) not only remains the main cause of late mortality after allogeneic hematopoietic cell transplant, but also has the capacity of causing severe organ impairment in those who survive. The Notch, a highly conserved ligand-receptor pathway, is involved in many immunological processes, including inflammatory and regulatory responses. Recently, mouse models have shown that the blockage of canonical Notch signaling prevents GvHD.
Objective and method: Due to the lack of data on the Notch pathway in human chronic GvHD, we sought to study the expression of NOTCH components in primary samples of patients who received allo-HCT and presented active cGvHD or a long-term clinical tolerance to cGvHD.
Results: Our results showed a significantly lower expression of NOTCH components in both groups that received allo-HCT, independently of their cGvHD status, when compared to healthy controls.
Conclusion: Moreover, there were no differences in gene expression levels between the active cGvHD and clinically tolerant groups. To our knowledge, this is one of the first studies performed in human primary samples and our data indicate that much remains to be learned regarding NOTCH signaling as a new regulator of GvHD.
Keywords: Allogeneic hematopoietic cell transplant; Chronic graft-versus-host-disease; Notch; Tolerance.
Copyright © 2022. Published by Elsevier España, S.L.U.
Conflict of interest statement
Conflicts of interest None.
Figures



Similar articles
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia.Clin Cancer Res. 2015 May 1;21(9):2020-8. doi: 10.1158/1078-0432.CCR-14-0586. Epub 2014 Oct 27. Clin Cancer Res. 2015. PMID: 25348512 Free PMC article.
-
Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.Ann Hematol. 2021 Mar;100(3):763-777. doi: 10.1007/s00277-021-04428-9. Epub 2021 Jan 25. Ann Hematol. 2021. PMID: 33491135 Free PMC article.
-
Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.Eur J Haematol. 2013 Aug;91(2):129-34. doi: 10.1111/ejh.12149. Epub 2013 Jun 28. Eur J Haematol. 2013. PMID: 23710658
-
Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation.Radiat Oncol. 2022 Nov 29;17(1):195. doi: 10.1186/s13014-022-02161-9. Radiat Oncol. 2022. PMID: 36447269 Free PMC article.
References
-
- Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76(9):1867-71. - PubMed
-
- Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(4):215–233. - PubMed
-
- Radtke F, MacDonald HR, Tacchini-Cottier F. Regulation of innate and adaptive immunity by Notch. Nat Rev Immunol. 2013;13(6):427–437. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous